Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

NCT03323151 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT03323151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03323151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Lead sponsor
PrECOG, LLC.
Phase
Phase 1/2
Overall status
Completed
Start date
August 13, 2018
Completion date
September 7, 2023
Enrollment
43 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

mantle-cell lymphoma